Newly Published Study Shows Parsortix Cell Separation System is Effective at Isolating Circulating Tumor Cells for Metastatic...
September 23 2015 - 2:15PM
Business Wire
The Study, published in PLOS ONE,
demonstrates a method that allows Parsortix to capture more CTCs at
comparable speeds to the existing clinical system while also
overcoming the limitations of EpCAM-based approaches for detecting
metastatic cancer
Research conducted at Barts Cancer Institute, Queen Mary
University, London, published today in PLOS ONE demonstrates that
the Parsortix Cell Separation System from ANGLE plc, showed
comparable speed – approximately two hours – in capturing
circulating tumor cells (CTCs) for prostate cancer compared to
bead-based epithelial cell adhesion molecule (EpCAM) antibody CTC
capturing systems, while also showing improved capture of CTCs that
are responsible for metastatic cancer.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150923005188/en/
ANGLE Parsortix™ System (Photo: Business
Wire)
The research team led by Dr. Yong-Jie Lu at Barts developed an
optimized sample preparation method for the capture of CTCs from
blood samples from patients with prostate cancer and healthy blood
samples spiked with prostate cancer cells. Their research
demonstrated that employing their method allowed the Parsortix
system to process samples at a speed and sample volumes comparable
to the standard CellSearch system typically used in the clinical
setting, while also demonstrating the ability to harvest CTCs not
only with epithelial features, but also those in the process of, or
that had completed, epithelial-to-mesenchymal transition (EMT) – a
significant finding that will provide more information for the
detection and treatment of metastatic cancer.
“Understanding how molecular alterations in cancer cells change
and evolve during cancer progression and in response to first-line
therapeutics is vital to better understanding cancer progression
and improving how we care for patients with metastatic disease,”
said Andrew Newland, CEO of ANGLE, plc. “However, current
bead-based EpCAM antibody CTC capturing systems have a critical
limitation. During cancer metastasis, EMT occurs to increase the
invasion capability of cancer cells, which leads to the loss of
epithelial markers, such as EpCAM and their replacement with
mesenchymal markers. The Parsortix microfluidic system captures
CTCs based on their size and deformability – not cell membrane
expressed proteins – and can capture the cells that have completed
EMT to allow for more precise monitoring of cancer
progression.”
Currently, CTC isolation is still mainly based on EpCAM
expression on epithelial origin cancer cells. New research,
however, indicates EMT is more and more recognized to play an
important role in metastasis and that certain EMT cancer cells lose
EpCAM expression. Isolation by techniques that are independent of
marker expression, such as Parsortix, may help to capture those EMT
CTCs.
CTC clusters have been reported to have increased metastatic
potential, be more resistant to apoptosis and be correlated with
poorer prognosis compared to single CTCs. In Parsortix isolated
samples, the researchers also observed clusters of more than three
CTCs. The ability to obtain CTC clusters will help to understand
the metastasis progenitor and to predict patient prognosis.
The Barts researchers used prostate cancer as a cancer model to
optimize and evaluate the Parsortix size and deformability-based
system for CTC isolation and compared its efficiency with two other
leading CTC systems, IsoFlux from Fluxion Biosciences and
CellSearch from Janssen DX. Based on the current generally accepted
definition of CTCs as CK positive, CD45 negative, nucleated and
morphologically intact cells, CellSearch harvested the least CTCs
among the three platforms, while the number of CTCs harvested by
IsoFlux and Parsortix showed no statistically significant
difference. Parsortix, however, showed significantly higher purity
of harvested CTCs compared to IsoFlux, which makes downstream
analysis easier.
The research also indicates that employing Parsortix can avoid
potential problems in downstream analysis of CTCs caused by the
magnetic beads used by CellSearch and IsoFlux.
“For example, in immunofluorescence analysis, beads adhering to
the cell membrane and covering on the top of the cells prohibits
effective immunostaining for membrane proteins,” said lead
researcher Yong-Jie Lu. “Auto-fluorescence from the beads also
affects CTC analysis using fluorescence markers, such as
immunofluorescence and fluorescence in situ hybridization. The
bead-free systems avoid these problems in downstream CTC
analysis.”
“The easy to use, epitope-independent Parsortix system not only
captures clinically-relevant CTCs of all different phenotypes but
it allows their easy harvesting for downstream analysis.
Furthermore the cells are undamaged and we have shown them to be
viable for cell culture.”
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the Parsortix system, a cell separation technology that enables a
simple blood test to capture targeted cells, such as circulating
tumor cells (CTCs) for molecular profiling and analysis. Parsortix
can help deliver targeted cancer diagnostics designed to inform
personalized treatment of cancer. It is also designed to be
compatible with existing major medtech analytical platforms and to
act as a companion diagnostic for major pharma in helping to
identify patients that will benefit from a particular drug and then
monitoring the drug’s effectiveness. ANGLE has established formal
collaborations with world-class cancer centers and is working with
these cancer centers to demonstrate key applications for its
Parsortix non-invasive cancer diagnostic system as a liquid biopsy.
In addition to cancer cells, the Parsortix technology has the
potential for deployment for other clinically significant cell
types in the future.
ANGLE’s Parsortix system is available for research use worldwide
and is CE-IVDD Marked for indicated clinical use in Europe. The
Company’s first clinical application is in ovarian cancer.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and in the United
States on the OTC-QX market under the ticker symbol ANPCY.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150923005188/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice
PresidentorMedia:Brandwidth Solutions LLCChris Anderson,
207-232-7007canderson@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024